New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
09:36 EDTAEGREMA rejection bodes well for Aegerion, says Deutsche Bank
Deutsche Bank said the European Medicines Agency's rejection of the re-examination request for Mipomersen in Homozygous Familial Hypercholesterolemia bodes well for the approval of Aegerion's Lomitapide in Europe. The firm reiterates a Buy rating on Aegerion with a $41 price target.
News For AEGR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
09:28 EDTAEGRAegerion board backs CEO amid drug claims, TheStreet reports
Subscribe for More Information
October 27, 2014
10:52 EDTAEGRSeattle Genetics, Aegerion CEOs accused of drug use in lawsuit, TheStreet says
Subscribe for More Information
October 22, 2014
07:35 EDTAEGRCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 20, 2014
07:24 EDTAEGRAegerion price target lowered to $46 from $66 at Leerink
Leerink lowered its price target for Aegerion shares to $46 after its survey of 40 U.S. cardiologists implied a more bearish outlook for Juxtapid once PCSK9s emerge. The firm, however, believes new patient adds are well outpacing Juxtapid discontinuations in the near term. It keeps an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use